Sign up USA
Proactive Investors - Run By Investors For Investors

Theralase to expand bladder cancer trial after initial success

Theralase's Photo Dynamic Therapy technology is a "search and destroy" treatment for cancer cells
Bladder pain
The primary and secondary objectives for the first part of the non-muscle invasive bladder cancer clinical study were successfully met

The first part of cold laser technology firm Theralase Technologies Inc’s (CVE:TLT) phase Ib bladder cancer trial has gone well.

The primary and secondary objectives for the first part of the non-muscle invasive bladder cancer (NMIBC) clinical study were successfully met, the independent data and safety monitoring board unanimously determined.

The plan now is to sign-up another six patients for the second part of the study, in which they will be treated with a therapeutic dose of the photo dynamic compound (PDC) for NMIBC using Theralase’s photo dynamic therapy (PDT) technology.

READ Laser specialist TheraLase Technologies primed for a pivotal year

"I am delighted that a small Canadian company, such as Theralase, has been able to achieve such significant clinical results and in such a short time span. I look forward to Theralase reporting out on the next six patients using the therapeutic dose," said Dr Michael Jewett, uro-oncologist at the University Health Network.

Theralase’s boss and founder, Roger Dumoulin-White, thanked the data and safety monitoring board for performing the review.

“Theralase looks forward to successfully reporting out on the performance to the primary and secondary endpoints for the next six patients and also the exploratory objective of efficacy of all nine patients, as more clinical data is collected,” Dumoulin-White said.

“Theralase has now successfully transformed from a pre-clinical to a clinical oncology organization,” he added.

View full TLT profile View Profile

Theralase Technologies Inc. Timeline

Related Articles

Digital marketing
September 11 2017
Lots of marketing groups have pursued a 'buy and build' strategy and have become cumbersome as a result; Be Heard puts the emphasis on maintaining agility
June 18 2017
Brendan Martin talked underwater drone technology and commercialisation.
August 09 2017
The Power and Electromechanical (P&EM) business's unaudited backlog was $19.2mln as at end June

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use